Description: Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical devices for applications in the areas of advanced wound care, surgical and diagnostics, and drug delivery comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology; SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures; and EmboCept M, a device for use in the treatment of benign prostatic hyperplasia. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company was founded in 1944 and is headquartered in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.
Home Page: www.maglechemoswed.com
Agneslundsvägen 27
Malmö,
212 15
Sweden
Phone:
46 40 38 33 00
Officers
| Name | Title |
|---|---|
| Mr. Justin Pierce | Chief Exec. Officer |
| Ms. Petra Jonsson Sjolin | Chief Financial Officer |
| Mr. Fredrik Andersson | Chief Operations Officer |
| Ms. Helena Ossmer Thedius | Chief Marketing & Innovation Officer |
| Mr. Simon Jegou | Chief Strategy Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 29.7826 |
| Price-to-Book MRQ: | 2.0132 |
| Price-to-Sales TTM: | 2.2178 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 69 |